Favipiravir: A New Medication for the Ebola Virus Disease Pandemic

Takashi Nagata, Alan K. Lefor, Manabu Hasegawa, Masami Ishii

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of this report is to advocate speedy approval and less stringent regulations for the use of experimental drugs such as favipiravir in emergencies. Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. Although favipiravir is one of the choices for the treatment of patients with Ebola virus, several concerns exist. First, a clinical trial of favipiravir in patients infected with the Ebola virus has not yet been conducted, and further studies are required. Second, favipiravir has a risk for teratogenicity and embryotoxicity. Therefore, the Ministry of Health, Welfare and Labor of Japan has approved this medication with strict regulations for its production and clinical use. However, owing to the emerging Ebola virus epidemic in West Africa, on August 15, 2014, the Minister of Health, Welfare and Labor of Japan approved the use of favipiravir, if needed.

Original languageEnglish
Pages (from-to)79-81
Number of pages3
JournalDisaster Medicine and Public Health Preparedness
Volume9
Issue number1
DOIs
Publication statusPublished - Oct 7 2015
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Pandemics
Ebolavirus
Japan
Lassa Fever
H1N1 Subtype Influenza A Virus
Western Africa
Health
Orthomyxoviridae
Antiviral Agents
favipiravir
Emergencies
Fever
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Favipiravir : A New Medication for the Ebola Virus Disease Pandemic. / Nagata, Takashi; Lefor, Alan K.; Hasegawa, Manabu; Ishii, Masami.

In: Disaster Medicine and Public Health Preparedness, Vol. 9, No. 1, 07.10.2015, p. 79-81.

Research output: Contribution to journalArticle

Nagata, Takashi ; Lefor, Alan K. ; Hasegawa, Manabu ; Ishii, Masami. / Favipiravir : A New Medication for the Ebola Virus Disease Pandemic. In: Disaster Medicine and Public Health Preparedness. 2015 ; Vol. 9, No. 1. pp. 79-81.
@article{f6bfc6517db74e52a4ef3beb81593517,
title = "Favipiravir: A New Medication for the Ebola Virus Disease Pandemic",
abstract = "The purpose of this report is to advocate speedy approval and less stringent regulations for the use of experimental drugs such as favipiravir in emergencies. Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. Although favipiravir is one of the choices for the treatment of patients with Ebola virus, several concerns exist. First, a clinical trial of favipiravir in patients infected with the Ebola virus has not yet been conducted, and further studies are required. Second, favipiravir has a risk for teratogenicity and embryotoxicity. Therefore, the Ministry of Health, Welfare and Labor of Japan has approved this medication with strict regulations for its production and clinical use. However, owing to the emerging Ebola virus epidemic in West Africa, on August 15, 2014, the Minister of Health, Welfare and Labor of Japan approved the use of favipiravir, if needed.",
author = "Takashi Nagata and Lefor, {Alan K.} and Manabu Hasegawa and Masami Ishii",
year = "2015",
month = "10",
day = "7",
doi = "10.1017/dmp.2014.151",
language = "English",
volume = "9",
pages = "79--81",
journal = "Disaster Medicine and Public Health Preparedness",
issn = "1935-7893",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Favipiravir

T2 - A New Medication for the Ebola Virus Disease Pandemic

AU - Nagata, Takashi

AU - Lefor, Alan K.

AU - Hasegawa, Manabu

AU - Ishii, Masami

PY - 2015/10/7

Y1 - 2015/10/7

N2 - The purpose of this report is to advocate speedy approval and less stringent regulations for the use of experimental drugs such as favipiravir in emergencies. Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. Although favipiravir is one of the choices for the treatment of patients with Ebola virus, several concerns exist. First, a clinical trial of favipiravir in patients infected with the Ebola virus has not yet been conducted, and further studies are required. Second, favipiravir has a risk for teratogenicity and embryotoxicity. Therefore, the Ministry of Health, Welfare and Labor of Japan has approved this medication with strict regulations for its production and clinical use. However, owing to the emerging Ebola virus epidemic in West Africa, on August 15, 2014, the Minister of Health, Welfare and Labor of Japan approved the use of favipiravir, if needed.

AB - The purpose of this report is to advocate speedy approval and less stringent regulations for the use of experimental drugs such as favipiravir in emergencies. Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. Although favipiravir is one of the choices for the treatment of patients with Ebola virus, several concerns exist. First, a clinical trial of favipiravir in patients infected with the Ebola virus has not yet been conducted, and further studies are required. Second, favipiravir has a risk for teratogenicity and embryotoxicity. Therefore, the Ministry of Health, Welfare and Labor of Japan has approved this medication with strict regulations for its production and clinical use. However, owing to the emerging Ebola virus epidemic in West Africa, on August 15, 2014, the Minister of Health, Welfare and Labor of Japan approved the use of favipiravir, if needed.

UR - http://www.scopus.com/inward/record.url?scp=84924630804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924630804&partnerID=8YFLogxK

U2 - 10.1017/dmp.2014.151

DO - 10.1017/dmp.2014.151

M3 - Article

C2 - 25544306

AN - SCOPUS:84924630804

VL - 9

SP - 79

EP - 81

JO - Disaster Medicine and Public Health Preparedness

JF - Disaster Medicine and Public Health Preparedness

SN - 1935-7893

IS - 1

ER -